New names, new narratives: Why biotechs decide to rebrand By Willow Shah-Neville 13 minutesmins June 15, 2026 13 minutesmins Share WhatsApp Twitter Linkedin Email Photo credits: davisuko Newsletter Signup - Under Article / In Page"*" indicates required fieldsPhoneThis field is for validation purposes and should be left unchanged.Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*Company name*Job title*Business email* Over the past year, a growing number of companies have relaunched under fresh brands, often accompanied by promises of a new chapter, renewed focus, or a transformed business strategy. On the surface, these biotech rebranding announcements can look similar: a new corporate identity, a redesigned website, and a narrative centered on future opportunities. But a company changing its name can mean very different things, whether that be a complete strategic reset, a pivot to a smaller part of the business and getting rid of what did not work, or an attempt to capture investor enthusiasm. Table of contentsThe three main reasons behind biotech rebrands For some biotech companies, a rebrand is the public face of a strategic restructuring after years of pursuing a business model that failed to deliver on its promise. For others, it marks a dramatic pivot into an entirely new area in pursuit of growth and investor interest. Meanwhile, in other cases, a relaunch reflects a narrower but potentially more sustainable future, with a company shedding less successful operations and doubling down on the parts of the business that continue to generate value. Three recent examples illustrate just how different those transformations can be. While each company emerged with a new name and a new story to tell, the business realities behind those changes reveal three distinct approaches to reinvention. A complex strategic restructuring: Galapagos becomes Lakefront Among the recent wave of biotech rebrandings, the transformation of Galapagos into Lakefront Biotherapeutics – after 27 years of carrying the name of the well-known tortoise and islands – is perhaps the clearest example of a company using a new identity to mark a fundamental strategic reset. The name change, announced in May, followed a 12-month period in which the Belgian biotech company considered a spinout, switched chief executive officers (CEOs), and entered a three-way acquisition agreement to acquire Ouro Medicines with Gilead. Lakefront’s cell therapy unit was at the heart of this restructuring. At the start of 2025, the company planned to split into two separate businesses, one of which would be focused on its cell therapy portfolio. However, things did not go to plan. After exploring a range of alternatives, including a potential sale of the business, the company concluded that it could not find a buyer or investor capable of taking the unit forward on acceptable terms. Instead, management opted to wind down the cell therapy operation altogether in October 2025 and redirect resources toward new business development opportunities – something that several companies have done in recent times as the cell therapy field loses the pull it once had due to issues like high manufacturing costs, complex logistics, and mounting safety risks. Nevertheless, Lakefront’s decision signaled a significant retreat. At the time of the exit, cell therapy was involved in seven of the 10 indications the company was pursuing across its pipeline. This meant that cutting those therapies only left the company with three small molecule assets in development, targeting diseases like systemic lupus erythematosus, inflammatory bowel disease, and undisclosed autoimmune and inflammatory conditions. Additionally, the wind-down affected hundreds of employees across Europe, the U.S., and China and resulted in the closure of multiple research and operational sites. Lakefront also said it expected to incur costs of €150 million to €200 million ($174 million to $232 million) in one-time restructuring expenses, as well as €100 million to €125 million ($116 million to $145 million) in operating costs from the fourth quarter of 2025 through 2026. Suggested Articles Biotech risk management: The hidden risks behind layoffs 12 AI drug discovery companies you should know about A wave of biotech layoffs: will the trend continue throughout 2024? Zombie biotechs and the mission to make them disappear fast Seven biotechs in Belgium making leaps in the clinic Ultimately, company executives framed the move as the outcome of a comprehensive strategic review and argued that reallocating capital away from the cell therapy business offered the best path toward a sustainable future. Following the completion of employee consultation processes, the board formally approved the wind-down and repositioned the remaining organization around what it described as “transformative business development.” Indeed, some would argue that the rebrand and restructuring were necessary; despite having been in business for more than a quarter of a century, Galapagos had yet to secure a product approval. In this context, the transition from Galapagos to Lakefront was about much more than branding. Rather than signaling expansion into a new area, the new name marked the end of a major strategic bet and the beginning of a much leaner organization built around a different vision for growth. It illustrates how, in today’s biotech market, rebranding can sometimes serve as a public acknowledgement that a company has chosen to move on from a strategy that failed to deliver the results it had hoped for. Chasing a new opportunity: Hoth rebrands as Rocket One If Lakefront represents a company retreating from a failed strategy, Hoth Therapeutics’ rebrand illustrates a very different type of corporate reinvention: a dramatic pivot into an entirely new sector. In May 2026, Hoth became Rocket One and expanded beyond biotech into the space industry. The company said that its strategic focus would now become the next generation of satellites, defense platforms, and space-based artificial intelligence (AI) systems that depend on hardware capable of operating reliably in space. As a biotech company, Hoth had been developing a neurokinin 1 receptor agonist for EGFR inhibitor-induced skin toxicities, but it had yet to report any revenue from its operations and posted a net loss of more than $2.6 million in the March quarter. Meanwhile, an intended merger with Algorithm Sciences back in 2023 also fell through, and even a potential play in the obesity space through a clinical-stage parenteral glial cell-derived neurotrophic factor program left investors cold in April. Essentially, the company was on rocky terrain and running out of options – hence its dramatic pivot. Fortunately for Rocket One, the market response was immediate; its shares jumped almost 40%, highlighting the enthusiasm that can accompany moves into sectors perceived as offering greater growth potential than the biotech market. The reaction also underscored a broader reality of public markets: in some circumstances, the promise of a new narrative can be almost as powerful as operational results. Yet Rocket One’s transformation was not a complete abandonment of its biotech roots. Alongside the rebrand, the company stated that it intended to continue its existing biotech activities through a separate subsidiary. This means that, unlike a company that exits one industry entirely in order to enter another, Rocket One wanted to preserve its biotech assets while ultimately pursuing a radically different growth story to rid it of its financial struggles. Although the frenzy around the space economy is relatively new (in large part thanks to Elon Musk’s SpaceX), AI has been a dominant theme for some time now, with several small companies whose legacy businesses have no connection to AI announcing a pivot. While this has led to a near-term spike, shares of some of these companies have failed to hold onto the gains. Therefore, we will have to wait and see how well Rocket One can navigate this new journey into space and AI technology, and whether it will truly be able to hold onto long-term growth. Saving the part that works: Molecular Health’s business unit relaunches under Lucera Unlike the transformations at Lakefront and Rocket One, the creation of Lucera was not strictly a rebrand. Instead, it represented the continuation of a viable business unit from a company that had struggled commercially, despite having a strong core technology. The company in question was called Molecular Health, which was founded in 2005 with the goal of helping healthcare and life sciences organizations make sense of the growing volume of molecular and clinical data being generated following the sequencing of the human genome. To achieve this aim, the biotech ended up developing Dataome, a comprehensive clinical-molecular reference database designed to integrate knowledge about diseases, therapies, and drugs into a single platform. The technology is now owned exclusively by Lucera, a newly formed company intended to continue Molecular Health’s legacy with Dataome. Lucera’s CEO, Friedrich von Bohlen, explained to Labiotech how this move came about: “The main investor in Molecular Health was dievini Hopp Biotech holding GmbH & Co. KG, Dietmar Hopp’s biotech investment company. Already several years ago, dievini had decided to not further invest in biotech. A group of institutional and private investors was interested in the drug development part of Molecular Health and eventually bought out this business unit of Molecular Health, which was formed as a new and independent company, Lucera.” According to von Bohlen, these new investors bring industry expertise and fresh money, which will allow Lucera to grow and expand the business. Meanwhile, the move also allows the company to focus exclusively on decision intelligence for drug development, rather than dividing resources between two very different businesses. “Commercial, organizational, and technology investments can now be distinctly directed to this market and will enable us to grow and expand the business.” So, rather than retreating from a failed strategy or pursuing a dramatic new sector, Lucera has emerged from a process of simplification. By shedding a broader corporate structure and concentrating on the business that investors believed had the strongest prospects, Lucera shows how a relaunch can be used to sharpen focus rather than simply change direction. “In our case, we are talking not just about rebranding but about the formation of a newco [new company], which has allowed us to position Lucera clean and clear without the former diagnostics business, which has become a commodity and faces different competition,” said von Bohlen. “Clarity, focus, and agility are so much easier now. With efficacy and efficiency in drug development still poor today, it’s a large field that can prosper from the superior data intelligence that Lucera has to offer.” A wave of biotech rebrands in the last year These three companies are not the only ones to rebrand or relaunch in the last year. A few other examples, among many, include: Bluebird bio’s rebrand to Genetix Biotherapeutics, which saw the company return to its origins (it began life as Genetix Pharmaceuticals in 1992) following its acquisition by a pair of private equity firms; Onco3R Therapeutics’ rebrand to Coultreon Biopharma, landing the company $125 million in series A funding; and MEI Pharma’s rebrand to Lite Strategy, as it expanded its business model beyond oncology drug development to focus on digital asset treasury startegies, backed by a $100 million Litecoin investment. The recent wave of biotech rebrands ultimately highlights the pressures that the sector is currently experiencing. Over the past several years, the biotech industry has faced a very different environment from the one that fueled the industry’s boom during the COVID-19 pandemic. As investment capital became harder to secure and public market valuations came under pressure, many biotech companies were forced to reassess their strategies. In some cases, that has meant cutting programs, reducing headcount, or abandoning entire therapeutic areas. In others, companies have decided to focus on their strongest assets, divesting non-core operations and concentrating resources instead on the businesses most likely to generate revenue and attract investors. A rebrand can serve as a powerful way to communicate those changes; it allows a company to signal a break from a previous strategy, emphasize a new area of focus, or present itself to investors through a different lens. Additionally, von Bohlen believes that the wave of rebrands is a reflection of AI market dynamics. “AI will change everything – but it will not replace everything. The whole TechBio field at this moment is conquering new untapped areas. On the one side, you need to be fast; on the other side, you need to create lasting value for your clients and partners. If you see you’re about to miss the best track, a reset is sometimes easier than a turn-around.” Ultimately, in an industry where scientific setbacks, funding challenges, and shifting investor sentiment can quickly alter a company’s prospects, reinvention is increasingly becoming an important strategy instead of just a branding or marketing exercise. Can rebrands really turn a company around? While the recent wave of biotech rebrands may suggest an ongoing trend, the ultimate question is: can rebrands truly help to turn a company around? For some companies, it certainly can. As mentioned, rebranding is a way to signal a strategic reset that can attract the interest of new investors; if the restructuring has truly been successful, then it will allow a company to have the fresh start it needs, paving a new path with a better focus. What a rebrand cannot do, however, is solve the underlying challenges that a company was already facing. A new identity may help clarify strategy, communicate change, or generate market interest, but long-term success will ultimately depend on execution. Investors will still be looking for clinical progress, sustainable revenue, operational discipline, and evidence that the new direction is delivering results. If the reset was not conducted thoroughly enough, the company could simply fall back into its old ways and, even if investors seemed interested in the rebranding at first, they may eventually pull out again. According to von Bohlen, distinguishing between a rebrand that reflects a real strategic transformation and one that is essentially a marketing exercise, or perhaps even a cash grab, comes down to a question of motivation. “In self-reflection of changing market conditions: are you reacting to a true strategic shift that you are convinced can be best approached with a repositioning, including clear and new messaging to internal and external audiences? Or are you only trying to paint over what hasn’t been as successful as you had originally thought?” The recent crop of biotech relaunches, therefore, offers a useful reminder: when a company changes its name, the most important question is not what it is called, but what has actually changed underneath, and whether the road the company has set out on is genuinely a viable strategy for long-term growth. The answer may reveal far more about the state of the business – and the state of the industry – than any logo or corporate slogan ever could. This article is reserved for subscribers Subscribe for free to continue reading.Enter your details to log in or subscribe. Email Company name Job title Continue Readingor Continue with Microsoft Continue with LinkedIn By continuing, I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy. Discover how AI is transforming drug discovery & development Join our on-demand webinar to explore how AI-powered tools and integrated workflows are reshaping modern drug discovery & development. Hear from Samar Noor (Bristol Myers Squibb), Julie Gerardi (Bioptimus), and Barry A. Bunin (Collaborative Drug Discovery) as they share real-world insights into how scientists are using AI to design better molecules, predict outcomes more efficiently, optimize experiments, and make smarter, data-driven decisions, while effectively managing research data and safeguarding IP. Watch now Explore other topics: Artificial intelligenceCell therapy ADVERTISEMENT